Determine Found Non-Compliant With Nasdaq

Posted: Updated:
CARMEL -

Carmel-based Determine Inc. (Nasdaq: DTRM) is facing procedures that could ultimately result in the company being delisted from The Nasdaq Stock Market. The tech company says it has received a notification letter from Nasdaq saying it is out of compliance due to its continuous low stock price.

In a filing with the U.S. Securities and Exchange Commission, the company says the letter was issued after its common stock had closed below $1 per share for 30 consecutive days. The price of $1 per share is the minimum required closing bid price for continued listing on The Nasdaq Capital Market.

Determine says the notice from Nasdaq has no immediate effect on its listing, and the company has 180 calendar days to regain compliance. In order to become compliant, the closing bid price of Determine's stock must be at least $1 per share for a minimum of 10 consecutive business days.

If the company does not regain compliance by March 25, 2019, it may be eligible for additional time to regain compliance or it may request a hearing before a Nasdaq Hearings Panel.

Determine announced in June 2016 it would relocate its global headquarters from California to Carmel. The following year, the company announced a stock offering in an effort to raise nearly $5 million. 

  • Perspectives

    • Owe Taxes? What Went Wrong in 2018 and How to Survive It

      The 2018 tax filing deadline came and went. Whew! But for some Americans, the tax headache has just begun. This year was the first filing under the Tax Cuts and Jobs Act and while some taxpayers saw larger refunds others received a rude awakening. If you’re reeling from a large tax burden, this article is for you. The Root of the Problem Remember how excited you were when you received your first paycheck—followed by dismay when you saw how much was taken out for taxes.

    More

Subscribe

Name:
Company Name:
Email:
Confirm Email:
HTML
INside Edge
Morning Briefing
BigWigs & New Gigs
Life Sciences Indiana
Indiana Connections
INPower
Subscribe
Unsubscribe

Events



  • Most Popular Stories

    • Photo of Gary City Hall courtesy of the City of Gary

      McDermott Details Gary Retail Desert

      The city of Gary is facing challenges as it tries to rejuvenate retail business in the city. In an interview with our partners at The Times of Northwest Indiana, Aaron McDermott, president of Latitude Commercial Real Estate Services in Schererville, says the challenge is due to the perception, proximity and demographics associated with Gary. 

    • The Landing project involves redeveloping seven buildings and two parking lots into a mixed-use development.

      New Restaurant Concept Coming to The Landing

      The developers of a $34 million redevelopment project in downtown Fort Wayne have announced a new partnership. Cincinnati-based The Model Group says it is working with Cunningham Restaurant Group to bring a "new and unique" restaurant experience to The Landing.

    • Ball State Among '30 Best Online MBA Degree Programs'

      Ball State University’s Miller College of Business has been recognized as one of The 30 Best Online MBA Degree Programs by MBA Central. The website details 30 programs across the nation and praises Ball State’s program for its variety and affordability.

    • Ryan Wagoner

      Profit With a Purpose: The Rise of Social Impact Investing

      Social impact investing is a fast-growing sector driven by investors who want to use private capital to further the public good. This industry provides a unique opportunity for results-oriented social entrepreneurs to invest in businesses, funds and nonprofits with the intention of generating positive, measurable social change alongside financial return. By engaging in impact investing, investors can align their investment portfolios with their philanthropic priorities.

    • Lilly and Avidity Biosciences Announce Partnership

      Indianapolis-based Eli Lilly and Co. (NYSE: LLY) and Avidity Biosciences Inc. have announced a new partnership. The global licensing and research collaboration will work toward the discovery, development and commercialization of new medicines in immunology and other areas.